Chemomab Therapeutics Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -94.6% over 5Y.
today you would have $48.74▼ -95.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.65 | $7.24 | $2.04 | $12.80 | |
| P/B | 77.5x | 77.0x | 201.7x | 34.1x | 78.1x |
| EPS | -$1.44 | -$3.44 | -$8.24 | -$9.68 | |
| ROE | -89.67% | -72.93% | -103.01% | -142.50% | -76.32% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| QNTMQuantum Biopharma Ltd. | $3.08 | — | 2.9x | — | -621.46% | $19.77M |
| NEUPNeuphoria Therapeutics Inc. | $3.76 | — | 0.7x | — | -62.90% | $20.32M |
| CCMConcord Medical Services Holdings Ltd | $4.76 | — | — | — | -21.88% | $20.67M |
| AKTXAkari Therapeutics Plc | $10.70 |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Company description provided by Yahoo Finance.
| — |
| 1.0x |
| — |
| -140.09% |
| $20.83M |
| KTTAPasithea Therapeutics Corp. | $0.56 | — | 0.4x | — | -65.49% | $18.71M |
| CTSOCytosorbents Corp | $0.34 | — | — | — | -336.21% | $21.09M |